MCID: MTR014
MIFTS: 58

Motor Neuron Disease malady

Categories: Neuronal diseases

Aliases & Classifications for Motor Neuron Disease

Aliases & Descriptions for Motor Neuron Disease:

Name: Motor Neuron Disease 38 12 52 14 69
Motor Neuron Diseases 51

Classifications:



External Ids:

Disease Ontology 12 DOID:231
ICD10 33 G12.2 G12.20
ICD9CM 35 335.2
MeSH 42 D016472
UMLS 69 C0085084

Summaries for Motor Neuron Disease

NINDS : 51 The motor neuron diseases (MNDs) are a group of progressive neurological disorders that destroy cells that control essential muscle activity such as speaking, walking, breathing, and swallowing.  Normally, messages from nerve cells in the brain (called upper motor neurons) are transmitted to nerve cells in the brain stem and spinal cord (called lower motor neurons) and from them to particular muscles.  When there are disruptions in these signals, the result can be gradual muscle weakening, wasting away, and uncontrollable twitching (called fasciculations).  Eventually, the ability to control voluntary movement can be lost.  MNDs may be inherited or acquired, and they occur in all age groups.  MNDs occur more commonly in men than in women, and symptoms may appear after age 40.  In children, particularly in inherited or familial forms of the disease, symptoms can be present at birth or appear before the child learns to walk.

MalaCards based summary : Motor Neuron Disease, also known as motor neuron diseases, is related to madras motor neuron disease and amyotrophic lateral sclerosis 1, and has symptoms including ataxia, muscular fasciculation and hemiplegia. An important gene associated with Motor Neuron Disease is TARDBP (TAR DNA Binding Protein), and among its related pathways/superpathways are Cytoskeletal Signaling and Neuroscience. The drugs Riluzole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include Neural Tube and Neural Tube, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A neurodegenerative disease that is located in the motor neurones.

Wikipedia : 71 A motor neuron disease (MND) is any of several neurological disorders that selectively affect motor... more...

Related Diseases for Motor Neuron Disease

Diseases related to Motor Neuron Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
id Related Disease Score Top Affiliating Genes
1 madras motor neuron disease 12.4
2 amyotrophic lateral sclerosis 1 11.9
3 lateral sclerosis 11.8
4 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 11.6
5 dementia, frontotemporal 11.6
6 progressive muscular atrophy 11.3
7 juvenile amyotrophic lateral sclerosis 11.3
8 spinal muscular atrophy, distal, autosomal recessive, 4 11.2
9 spinal muscular atrophy 11.1
10 spinal and bulbar muscular atrophy of kennedy 11.1
11 hereditary spastic paraplegia 11.1
12 neuropathy, distal hereditary motor, type viib 11.1
13 progressive bulbar palsy 11.0
14 neuronitis 11.0
15 amyotrophy, monomelic 10.9
16 spinal muscular atrophy, jokela type 10.7
17 pontocerebellar hypoplasia, type 1c 10.7
18 benign focal amyotrophy 10.7
19 silver spastic paraplegia syndrome 10.7
20 pick disease 10.7
21 o'sullivan-mcleod syndrome 10.7
22 supranuclear palsy, progressive 10.7
23 spastic paraplegia 39, autosomal recessive 10.7
24 patulous eustachian tube 10.7
25 dementia 10.5
26 posterior polar cataract 10.3 SMN1 SMN2
27 spinal cord glioma 10.3 SMN1 SMN2 TARDBP
28 fanconi anemia, complementation group g 10.3 ALS2 SOD1
29 colorado tick fever 10.3 SMN1 SMN2 TARDBP
30 protein r deficiency 10.3 GRN MAPT
31 gata1-related thrombocytopenia 10.3 GRN MAPT
32 social emotional agnosia 10.3 GRN TARDBP
33 spinal muscular atrophy-4 10.3 NAIP SMN1 SMN2
34 hereditary paraganglioma-pheochromocytoma syndromes 10.3 GRN MAPT
35 glomerulopathy with fibronectin deposits 2 10.3 ALS2 CNTF
36 pigmented nodular adrenocortical disease, primary, 3 10.3 SMN1 SMN2
37 color agnosia 10.3 GRN TARDBP
38 pseudohermaphrodism anorectal anomalies 10.3 NAIP SMN1 SMN2
39 sting-associated vasculopathy, infantile-onset 10.3 SOD1 TARDBP VCP
40 fanconi renotubular syndrome 1 10.3 MAPT RAB5A TARDBP
41 neurosarcoidosis 10.3 MAPT SLC1A2 SOD1
42 spinal muscular atrophy-3 10.3 NAIP SMN1 SMN2
43 osteogenesis imperfecta, type vi 10.3 SOD1 TARDBP
44 epithelioid type angiomyolipoma 10.2 CNTF MAPT SOD1 TARDBP
45 neuropathy 10.2
46 acrofrontofacionasal dysostosis 10.2 GRN MAPT TARDBP
47 adrenal cortical adenoma 10.2 SQSTM1 TARDBP VCP
48 postauricular lymphadenitis 10.2 GRN MAPT TARDBP
49 autoimmune disease of urogenital tract 10.2 GRN MAPT TARDBP
50 acne inversa, familial, 3 10.2 MAPT SQSTM1 TARDBP

Comorbidity relations with Motor Neuron Disease via Phenotypic Disease Network (PDN):


Amyotrophic Lateral Sclerosis 1

Graphical network of the top 20 diseases related to Motor Neuron Disease:



Diseases related to Motor Neuron Disease

Symptoms & Phenotypes for Motor Neuron Disease

UMLS symptoms related to Motor Neuron Disease:


ataxia, muscular fasciculation, hemiplegia, myoclonus

MGI Mouse Phenotypes related to Motor Neuron Disease:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 ALS2 AR BSCL2 CNTF DCTN1 GRN
2 cellular MP:0005384 10.32 AR BSCL2 CNTF DCTN1 GRN MAPT
3 homeostasis/metabolism MP:0005376 10.28 AR BSCL2 CNTF DCTN1 GRN HEXA
4 growth/size/body region MP:0005378 10.23 ALS2 AR BSCL2 HEXA MAPT SLC1A2
5 hematopoietic system MP:0005397 10.17 AR BSCL2 CNTF GRN MAPT RAB5A
6 immune system MP:0005387 10.11 TARDBP VCP ALS2 AR BSCL2 CNTF
7 mortality/aging MP:0010768 10 HEXA MAPT SLC1A2 SMN2 SOD1 SOD2
8 integument MP:0010771 9.92 VCP AR BSCL2 MAPT SMN2 SOD1
9 liver/biliary system MP:0005370 9.8 AR BSCL2 GRN HEXA SOD1 SOD2
10 muscle MP:0005369 9.61 ALS2 AR CNTF MAPT SMN2 SOD1
11 nervous system MP:0003631 9.53 DCTN1 GRN HEXA INA MAPT NEFH

Drugs & Therapeutics for Motor Neuron Disease

Drugs for Motor Neuron Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1744-22-5 5070
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Menthol Approved Phase 4 2216-51-5 16666
4
Mexiletine Approved Phase 4,Phase 2 31828-71-4 4178
5
Goserelin Approved Phase 4 65807-02-5 47725 5311128
6
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104632-26-0 59868 119570
7
Dextromethorphan Approved Phase 4,Phase 3,Phase 2 125-71-3 5360696 5362449
8
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2 93-14-1 3516
9
Cycloserine Approved Phase 4 68-41-7 401 6234
10 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1
11 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3
12 Excitatory Amino Acids Phase 4,Phase 2,Phase 3
13 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
17 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Phase 2
18 Antioxidants Phase 4,Phase 3,Phase 2,Phase 1
19 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
22 Hormones Phase 4,Phase 3,Phase 1,Phase 2
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
24 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2
25 Sodium Channel Blockers Phase 4,Phase 3,Phase 2
26 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Antimetabolites Phase 4,Phase 2,Phase 1
31 Antitussive Agents Phase 4,Phase 3,Phase 2
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2
33 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Adrenocorticotropic Hormone Phase 4,Phase 2
35 beta-endorphin Phase 4,Phase 2
36 Melanocyte-Stimulating Hormones Phase 4,Phase 2
37 Antitubercular Agents Phase 4
38 Renal Agents Phase 4
39
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585
40
Acetylcholine Approved Phase 3,Phase 2,Phase 1 51-84-3 187
41
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
42
Lenograstim Approved Phase 2, Phase 3 135968-09-1
43
Hydroxyurea Approved Phase 2, Phase 3,Phase 1 127-07-1 3657
44
Levodopa Approved Phase 3,Phase 2 59-92-7 6047
45
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 5460373 44475014
46
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
47
Quinidine Approved Phase 3,Phase 2 56-54-2 441074
48
Minocycline Approved, Investigational Phase 3,Phase 2 10118-90-8 5281021
49
Valproic Acid Approved, Investigational Phase 3,Phase 2,Phase 1 99-66-1 3121
50
Zinc Approved Phase 3,Phase 1,Phase 2 7440-66-6 32051 23994

Interventional clinical trials:

(show top 50) (show all 620)
id Name Status NCT ID Phase
1 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
2 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
3 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
4 CARE Canadian ALS Riluzole Evaluation Completed NCT00542412 Phase 4
5 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4
6 Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy Completed NCT00851461 Phase 4
7 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms Completed NCT00297778 Phase 4
8 Diaphragmatic Reinnervation of Tetraplegic Patients With Respiratory Insufficiency Completed NCT01350297 Phase 4
9 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Not yet recruiting NCT02462018 Phase 4
10 Enhancing STDP After Spinal Cord Injury Not yet recruiting NCT02701777 Phase 4
11 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4
12 Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis Unknown status NCT00706147 Phase 2, Phase 3
13 Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3
14 Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3
15 Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb Unknown status NCT01829763 Phase 3
16 Multicenter Rehabilitation Study in Acute Stroke Unknown status NCT00849303 Phase 2, Phase 3
17 Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Completed NCT01776970 Phase 2, Phase 3
18 LIME Study (LFB IVIg MMN Efficacy Study) Completed NCT01951924 Phase 3
19 Phase 3 Study of Dexpramipexole in ALS Completed NCT01281189 Phase 3
20 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
21 Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) Completed NCT00353665 Phase 2, Phase 3
22 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00125203 Phase 2, Phase 3
23 Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
24 A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3
25 Clinical Trial Ceftriaxone in Subjects With ALS Completed NCT00349622 Phase 3
26 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS Completed NCT00573443 Phase 3
27 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3
28 Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis Completed NCT00136110 Phase 3
29 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
30 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial Completed NCT00035815 Phase 3
31 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Completed NCT00330681 Phase 3
32 Safety Extension Study of TRO19622 in ALS Completed NCT01285583 Phase 2, Phase 3
33 Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT00868166 Phase 2, Phase 3
34 The Objective is to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Completed NCT02588677 Phase 2, Phase 3
35 The Effect of GCSF in the Treatment of ALS Patients Completed NCT01825551 Phase 2, Phase 3
36 Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis Completed NCT01492686 Phase 3
37 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls Completed NCT01160263 Phase 3
38 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00424463 Phase 3
39 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III Completed NCT00415519 Phase 3
40 Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS Completed NCT00372879 Phase 3
41 Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS Completed NCT00021697 Phase 3
42 A Trial of Hydroxyurea in Spinal Muscular Atrophy Completed NCT00485511 Phase 2, Phase 3
43 Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA) Completed NCT00774423 Phase 2, Phase 3
44 Escitalopram (Lexapro) for Depression MS or ALS Completed NCT00965497 Phase 3
45 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) Completed NCT02292537 Phase 3
46 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy Completed NCT02193074 Phase 3
47 Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients Completed NCT01645787 Phase 2, Phase 3
48 Evaluation of the Safety and Performance of the NESS L300 Plus System Completed NCT01237860 Phase 3
49 Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa Completed NCT00627640 Phase 3
50 MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Completed NCT00605683 Phase 3

Search NIH Clinical Center for Motor Neuron Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Motor Neuron Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Motor Neuron Disease:
Embryonic stem cell-derived motor neuron transplantation to treat paralysis
Embryonic/Adult Cultured Cells Related to Motor Neuron Disease:
Neuronal progenitor cells

Genetic Tests for Motor Neuron Disease

Anatomical Context for Motor Neuron Disease

MalaCards organs/tissues related to Motor Neuron Disease:

39
Spinal Cord, Brain, Eye, Testes, Breast, Skeletal Muscle, Cortex

The Foundational Model of Anatomy Ontology organs/tissues related to Motor Neuron Disease:

18
The Motor Neurones
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Motor Neuron Disease:
id Tissue Anatomical CompartmentCell Relevance
1 Neural Tube Motor Neural Progenitor Domain Motor Neural Progenitor Cells Potential therapeutic candidate
2 Neural Tube Motor Neural Progenitor Domain Motor Neurons Affected by disease

Publications for Motor Neuron Disease

Articles related to Motor Neuron Disease:

(show top 50) (show all 756)
id Title Authors Year
1
Motor neuron disease: Brain-computer interface unlocks the mind of a patient with ALS. ( 27909307 )
2017
2
Risk factors for respiratory failure of motor neuron disease in a multiracial Asian population. ( 28089419 )
2017
3
Hereditary spastic paraplegia: More than an upper motor neuron disease. ( 28449883 )
2017
4
Voltage-Gated Potassium Channel Antibodies in Slow-Progression Motor Neuron Disease. ( 27710962 )
2017
5
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. ( 28072907 )
2017
6
Motor neuron disease mortality and lifetime petrol lead exposure: Evidence from national age-specific and state-level age-standardized death rates in Australia. ( 27992849 )
2017
7
The death wish and motor neuron disease! The chameleons and new research optimism. ( 28084230 )
2017
8
Motor Neuron Disease Presenting With Acute Respiratory Failure: A Case Study. ( 28503469 )
2017
9
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease. ( 28067943 )
2017
10
Motor neuron disease: C9orf72 repeat expansion linked to aggressive disease in male patients with spinal-onset ALS. ( 27739539 )
2016
11
Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. ( 27834214 )
2016
12
Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. ( 28089114 )
2016
13
Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation. ( 27892702 )
2016
14
An autopsy-verified case of FTLD-TDP type A with upper motor neuron-predominant motor neuron disease mimicking MM2-thalamic-type sporadic Creutzfeldt-Jakob disease. ( 27929803 )
2016
15
Traumatic Brain Injury Results in Cellular, Structural and Functional Changes Resembling Motor Neuron Disease. ( 27566977 )
2016
16
Geographic distributions of motor neuron disease mortality and well water use in U.S. counties. ( 28019106 )
2016
17
Closing in on an infectious etiology of motor neuron disease. ( 27664984 )
2016
18
Development of patient decision support tools for motor neuron disease using stakeholder consultation: a study protocol. ( 27053272 )
2016
19
Motor neuron disease triggering takotsubo syndrome. ( 27525372 )
2016
20
CHCHD10 mutations and motor neuron disease: the distribution in Finnish patients. ( 27810918 )
2016
21
Neuromuscular Ultrasound in the Assessment of Polyneuropathies and Motor Neuron Disease. ( 27035248 )
2016
22
Neurofilaments in CSF As Diagnostic Biomarkers in Motor Neuron Disease: A Meta-Analysis. ( 27965574 )
2016
23
HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. ( 27664983 )
2016
24
Enacting Varieties of Subjectivity Through Practices of Care: A Story of Living With Motor Neuron Disease. ( 25918113 )
2016
25
The frontotemporal dementia-motor neuron disease continuum. ( 26987909 )
2016
26
Pigment retinopathy in warmblood horses with equine degenerative myeloencephalopathy and equine motor neuron disease. ( 27491953 )
2016
27
The End-of-Life Experiences of People with Motor Neuron Disease: Family Carers' Perspectives. ( 27135175 )
2016
28
Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease. ( 27188215 )
2016
29
Motor neuron disease: Nusinersen potentially effective in SMA. ( 28009016 )
2016
30
Quo vadis motor neuron disease? ( 27019797 )
2016
31
Eosinophilic Enteritis in Horses with Motor Neuron Disease. ( 27015868 )
2016
32
Trends in motor neuron disease: association with latitude and air lead levels in Spain. ( 27098242 )
2016
33
Angiotensin-converting enzyme inhibitors and motor neuron disease: An unconfirmed association. ( 26913547 )
2016
34
Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. ( 26538301 )
2016
35
WES in a family trio suggests involvement of TECPR2 in a complex form of progressive motor neuron disease. ( 27406698 )
2016
36
Advance care planning in motor neuron disease: A qualitative study of caregiver perspectives. ( 26847526 )
2016
37
Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population. ( 26905909 )
2016
38
Motor neuron disease mortality rates in U.S. states are associated with well water use. ( 27324739 )
2016
39
Abnormal response of distal Schwann cells to denervation in a mouse model of motor neuron disease. ( 26853136 )
2016
40
Concurrent Equine Degenerative Myeloencephalopathy and Equine Motor Neuron Disease in Three Young Horses. ( 27298214 )
2016
41
Motor neuron disease: Loss of MHCI exposes motor neurons to astrocyte-mediated toxicity. ( 26988907 )
2016
42
Executive dysfunction and survival in patients with amyotrophic lateral sclerosis: Preliminary report from a Serbian centre for motor neuron disease. ( 27494074 )
2016
43
Experiences and reflections of patients with motor neuron disease on breaking the news in a two-tiered appointment: a qualitative study. ( 26839121 )
2016
44
Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation. ( 27070121 )
2016
45
Motor neuron disease: Environmental toxins - modifiable risk factors for ALS? ( 27231185 )
2016
46
Scintigraphic Evaluation of Mild to Moderate Dysphagia in Motor Neuron Disease. ( 26914558 )
2016
47
"A monster that lives in our lives": experiences of caregivers of people with motor neuron disease and identifying avenues for support. ( 27125270 )
2016
48
Progress in respiratory management of bulbar complications of motor neuron disease/amyotrophic lateral sclerosis? ( 27520438 )
2016
49
Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. ( 27822919 )
2016
50
Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. ( 28040732 )
2016

Variations for Motor Neuron Disease

Expression for Motor Neuron Disease

Search GEO for disease gene expression data for Motor Neuron Disease.

Pathways for Motor Neuron Disease

Pathways related to Motor Neuron Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.04 DCTN1 MAPT RAB5A VCP
2 11.94 DCTN1 MAPT NEFH SLC1A2 SOD1 TARDBP
3
Show member pathways
11.37 DCTN1 INA NEFH
4
Show member pathways
11.08 ALS2 NEFH RAB5A SLC1A2 SOD1

GO Terms for Motor Neuron Disease

Cellular components related to Motor Neuron Disease according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.91 ALS2 AR DCTN1 SOD1 VCP
2 neuronal cell body GO:0043025 9.8 ALS2 MAPT NAIP RAB5A SOD1
3 perikaryon GO:0043204 9.72 NAIP SMN1 SMN2
4 neuron projection GO:0043005 9.65 ALS2 NAIP SMN1 SMN2 SOD1
5 myelin sheath GO:0043209 9.55 INA NEFH SOD1 SOD2 VCP
6 SMN-Sm protein complex GO:0034719 9.54 SMN1 SMN2
7 axolemma GO:0030673 9.52 MAPT SLC1A2
8 SMN complex GO:0032797 9.49 SMN1 SMN2
9 Gemini of coiled bodies GO:0097504 9.48 SMN1 SMN2
10 neurofilament GO:0005883 9.46 INA NEFH
11 somatodendritic compartment GO:0036477 9.43 MAPT RAB5A
12 axon GO:0030424 9.43 ALS2 CNTF MAPT NEFH RAB5A SLC1A2
13 neurofibrillary tangle GO:0097418 9.32 MAPT NEFH
14 cytoplasmic ribonucleoprotein granule GO:0036464 8.92 INA MAPT SMN1 SMN2
15 cytoplasm GO:0005737 10.24 ALS2 AR CNTF DCTN1 MAPT NAIP

Biological processes related to Motor Neuron Disease according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.67 ALS2 SOD1 SOD2
2 negative regulation of neuron apoptotic process GO:0043524 9.62 CNTF NAIP SOD1 SOD2
3 nuclear import GO:0051170 9.56 SMN1 SMN2
4 intermediate filament cytoskeleton organization GO:0045104 9.55 INA NEFH
5 positive regulation of microtubule polymerization GO:0031116 9.54 DCTN1 MAPT
6 superoxide anion generation GO:0042554 9.52 SOD1 SOD2
7 removal of superoxide radicals GO:0019430 9.51 SOD1 SOD2
8 nervous system development GO:0007399 9.5 CNTF DCTN1 INA NAIP SLC1A2 SMN1
9 hydrogen peroxide biosynthetic process GO:0050665 9.48 SOD1 SOD2
10 positive regulation of superoxide anion generation GO:0032930 9.46 MAPT SOD1
11 DNA-templated transcription, termination GO:0006353 9.43 SMN1 SMN2
12 response to axon injury GO:0048678 9.43 NAIP SOD1 SOD2
13 response to superoxide GO:0000303 9.4 SOD1 SOD2
14 astrocyte activation GO:0048143 9.37 CNTF MAPT
15 regulation of endosome size GO:0051036 9.16 ALS2 RAB5A
16 neurofilament cytoskeleton organization GO:0060052 8.8 INA NEFH SOD1

Molecular functions related to Motor Neuron Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.35 AR MAPT SOD1 SOD2 SQSTM1
2 identical protein binding GO:0042802 9.23 MAPT SMN1 SMN2 SOD1 SOD2 SQSTM1
3 superoxide dismutase activity GO:0004784 9.16 SOD1 SOD2

Sources for Motor Neuron Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....